These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26813076)

  • 1. Melanoma therapy: Check the checkpoints.
    Furue M; Kadono T
    J Dermatol; 2016 Feb; 43(2):121-4. PubMed ID: 26813076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
    An Q; Liu Z
    BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Devji T; Levine O; Neupane B; Beyene J; Xie F
    JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
    Mangana J; Cheng PF; Schindler K; Weide B; Held U; Frauchiger AL; Romano E; Kähler KC; Rozati S; Rechsteiner M; Moch H; Michielin O; Garbe C; Hauschild A; Hoeller C; Dummer R; Goldinger SM
    PLoS One; 2015; 10(10):e0139438. PubMed ID: 26426340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK inhibitors for the treatment of NRAS mutant melanoma.
    Sarkisian S; Davar D
    Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma.
    Schadendorf D; Fisher DE; Garbe C; Gershenwald JE; Grob JJ; Halpern A; Herlyn M; Marchetti MA; McArthur G; Ribas A; Roesch A; Hauschild A
    Nat Rev Dis Primers; 2015 Apr; 1():15003. PubMed ID: 27188223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
    Zhou AY; Johnson DB
    Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
    Thomas NE
    Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
    Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
    Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing melanoma therapeutics: overview and update.
    Korman JB; Fisher DE
    Wiley Interdiscip Rev Syst Biol Med; 2013; 5(3):257-71. PubMed ID: 23408545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
    Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
    Michielin O; Hoeller C
    Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
    Swe T; Kim KB
    Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.